Breast cancer drug Enhertu costs about £8,000 per session and is only available privately in England, but is offered on the ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

WHEN Sue Ware was planning her mum’s funeral after losing her to breast cancer, she never dreamed she would also get the disease.  But that’s exactly what happened. Just five days after her ...

Enhertu's approval extends to 75 nations, inclusive of the EU, for individuals with HER2 low metastatic breast cancer who have previously received systemic therapy or experienced disease ...

ENHERTU (5.4 mg/kg) is approved in more than 75 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.

This approval enables the use of Enhertu as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have ...

This approval enables the use of Enhertu as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have previously ...